RICE is an acronym for an anti-cancer treatment that expresses a combination chemotherapeutic regimen. This regimen is written variously as "R+ICE", "R-ICE", and "RICE."
RICE combination chemotherapy uses the following drugs
Rituximab is a monoclonal antibody that targets the CD20 protein on the surface of B-lymphocytes, while ifosfamide, carboplatin, and etoposide are all chemotherapeutic drugs that work at various stages of the cell cycle.
The RICE regimen is tailored to each individual patient, but is generally administered according to a 14 day cycle that is repeated three times:
Virtually all patients agree that RICE chemotherapy is an especially brutal chemotherapeutic regimen, with an immense amount of difficult side effects.
Most often, the RICE chemotherapeutic regimen is used as a preparative regimen in patients with non-Hodgkin's lymphomas of B-cell origin who are about to undergo a hematopoietic stem cell transplantation.
Photo: Pexels